聆听“普罗文奇”——一种昂贵的癌症治疗方法对未来医疗保险政策的启示。 - Suppr

Suppr

超能文献

Listening to Provenge--what a costly cancer treatment says about future Medicare policy.

作者信息

Chambers James D, Neumann Peter J

机构信息

Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA.

出版信息

N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.

DOI:10.1056/NEJMp1103057

PMID:21470004

Abstract

摘要

相似文献

Listening to Provenge--what a costly cancer treatment says about future Medicare policy.

N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.

Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.

Oncology (Williston Park). 2010 Sep;24(10):881-3.

Concerns about Provenge simmer as CMS ponders coverage.

J Natl Cancer Inst. 2011 Feb 16;103(4):288-9. doi: 10.1093/jnci/djr041. Epub 2011 Feb 8.

Provenge: revolutionary technology or ethical bust?

Hum Vaccin. 2011 Apr;7(4):477-80. doi: 10.4161/hv.7.4.14189. Epub 2011 Apr 1.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16.

Approval of provenge seen as first step for cancer treatment vaccines.

J Natl Cancer Inst. 2010 Aug 4;102(15):1108-10. doi: 10.1093/jnci/djq295. Epub 2010 Jul 28.

The Provenge decision.

Nat Clin Pract Oncol. 2007 Jul;4(7):381. doi: 10.1038/ncponc0854.

Provenge approval means sensitive coverage decisions.

Manag Care. 2010 Sep;19(9):31-4.

Cellular immunotherapy licensed for advanced prostate cancer.

Am J Health Syst Pharm. 2010 Jun 1;67(11):862. doi: 10.2146/news100039.

Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.

BioDrugs. 2015 Oct;29(5):301-7. doi: 10.1007/s40259-015-0140-7.

引用本文的文献

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.

Medicine (Baltimore). 2021 Apr 2;100(13):e24519. doi: 10.1097/MD.0000000000024519.

Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Pharmacoeconomics. 2020 Dec;38(12):1297-1308. doi: 10.1007/s40273-020-00956-w.

Mesenchymal Stem Cells Beyond Regenerative Medicine.

Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.

Immune reaction by cytoreductive prostatectomy.

Am J Clin Exp Urol. 2019 Apr 25;7(2):64-79. eCollection 2019.

Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.

Biomaterials. 2018 Nov;182:92-103. doi: 10.1016/j.biomaterials.2018.08.008. Epub 2018 Aug 6.

Hot-Spotters Aren't "The Problem"...But They Are Emblematic of the Failure of U.S. Healthcare.

J Gen Intern Med. 2017 Jan;32(1):6-8. doi: 10.1007/s11606-016-3846-4.

Opportunities to maximize value with integrated palliative care.

J Multidiscip Healthc. 2016 May 5;9:219-26. doi: 10.2147/JMDH.S90822. eCollection 2016.

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

J Manag Care Spec Pharm. 2016 Feb;22(2):163-70. doi: 10.18553/jmcp.2016.22.2.163.

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

J Clin Cell Immunol. 2015 Aug;6(4). doi: 10.4172/2155-9899.1000351. Epub 2015 Aug 26.

Adoptive T cell immunotherapy for cancer.

Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. doi: 10.5041/RMMJ.10179. eCollection 2015 Jan.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Listening to Provenge--what a costly cancer treatment says about future Medicare policy.

N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.

Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.

Oncology (Williston Park). 2010 Sep;24(10):881-3.

Concerns about Provenge simmer as CMS ponders coverage.

J Natl Cancer Inst. 2011 Feb 16;103(4):288-9. doi: 10.1093/jnci/djr041. Epub 2011 Feb 8.

Provenge: revolutionary technology or ethical bust?

Hum Vaccin. 2011 Apr;7(4):477-80. doi: 10.4161/hv.7.4.14189. Epub 2011 Apr 1.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16.

Approval of provenge seen as first step for cancer treatment vaccines.

J Natl Cancer Inst. 2010 Aug 4;102(15):1108-10. doi: 10.1093/jnci/djq295. Epub 2010 Jul 28.

The Provenge decision.

Nat Clin Pract Oncol. 2007 Jul;4(7):381. doi: 10.1038/ncponc0854.

Provenge approval means sensitive coverage decisions.

Manag Care. 2010 Sep;19(9):31-4.

Cellular immunotherapy licensed for advanced prostate cancer.

Am J Health Syst Pharm. 2010 Jun 1;67(11):862. doi: 10.2146/news100039.

Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.

BioDrugs. 2015 Oct;29(5):301-7. doi: 10.1007/s40259-015-0140-7.

引用本文的文献

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.

Medicine (Baltimore). 2021 Apr 2;100(13):e24519. doi: 10.1097/MD.0000000000024519.

Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Pharmacoeconomics. 2020 Dec;38(12):1297-1308. doi: 10.1007/s40273-020-00956-w.

Mesenchymal Stem Cells Beyond Regenerative Medicine.

Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.

Immune reaction by cytoreductive prostatectomy.

Am J Clin Exp Urol. 2019 Apr 25;7(2):64-79. eCollection 2019.

Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.

Biomaterials. 2018 Nov;182:92-103. doi: 10.1016/j.biomaterials.2018.08.008. Epub 2018 Aug 6.

Hot-Spotters Aren't "The Problem"...But They Are Emblematic of the Failure of U.S. Healthcare.

J Gen Intern Med. 2017 Jan;32(1):6-8. doi: 10.1007/s11606-016-3846-4.

Opportunities to maximize value with integrated palliative care.

J Multidiscip Healthc. 2016 May 5;9:219-26. doi: 10.2147/JMDH.S90822. eCollection 2016.

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

J Manag Care Spec Pharm. 2016 Feb;22(2):163-70. doi: 10.18553/jmcp.2016.22.2.163.

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

J Clin Cell Immunol. 2015 Aug;6(4). doi: 10.4172/2155-9899.1000351. Epub 2015 Aug 26.

Adoptive T cell immunotherapy for cancer.

Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. doi: 10.5041/RMMJ.10179. eCollection 2015 Jan.